" class="no-js "lang="en-US"> Andrew Hopkins - Medtech Alert
Thursday, March 28, 2024
Andrew Hopkins

Andrew Hopkins

About Andrew Hopkins

Andrew Lee Hopkins FRSE FRSC FRSB FLSW is a Welsh technology entrepreneur and biophysicist. He is the founder and Chief Executive Officer of Exscientia, a pharmatech company that uses artificial intelligence (AI) to efficiently discover new drugs. At Exscientia, Hopkins oversaw the discovery of the world’s first novel, precision engineered drug generated and optimized by AI, to enter human clinical trials.

Hopkins’s primary research interest is the science of drug discovery. His innovation in modern drug discovery informatics led to the development of machine learning and artificial intelligence to automate the design of drugs. Hopkins has pioneered several widely applied drug discovery concepts, such as the druggable genome, network pharmacology and ligand efficiency.

Hopkins is an honorary professor at the School of Life Sciences, University of Dundee, where previous he held the Chair of Medicinal Informatics and was the SULSA Research Professor of Translational Biology. He is also the former Director of Scottish Universities Life Sciences Alliance (SULSA).

Related Story

Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours

November 28 2022

Exscientia has announced clinical trial application (CTA) approval of IGNITE-AI, enabling site activation in its […]

EQRx and Exscientia Enter Strategic Drug Creation, Development, and Commercialization Collaboration to Accelerate the Advancement of New World-Class Medicines

June 25 2021

EQRx, a company committed to developing and delivering important new medicines to patients at radically […]

Exscientia Announces Second Molecule Created Using AI from Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial

May 13 2021

Exscientia Ltd. (Headquarters: Oxford, UK; CEO: Andrew Hopkins) is pleased to acknowledge that Sumitomo Dainippon Pharma Co., […]